Clinical Trial Update: Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selinexor in combination with the R-CHOP regimen as first-line therapy for TP53-mutated diffuse large B-cell lymphoma; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-CHOP regimen
• Selinexor (selinexor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING